KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Buildings (2016 - 2025)

Biogen has reported Buildings over the past 17 years, most recently at $2.1 billion for Q4 2025.

  • Quarterly results put Buildings at $2.1 billion for Q4 2025, up 8.99% from a year ago — trailing twelve months through Dec 2025 was $2.1 billion (up 8.99% YoY), and the annual figure for FY2025 was $2.1 billion, up 8.99%.
  • Buildings for Q4 2025 was $2.1 billion at Biogen, up from $2.0 billion in the prior quarter.
  • Over the last five years, Buildings for BIIB hit a ceiling of $2.1 billion in Q4 2025 and a floor of $1.6 billion in Q4 2022.
  • Median Buildings over the past 5 years was $1.7 billion (2021), compared with a mean of $1.8 billion.
  • Biggest five-year swings in Buildings: surged 65.78% in 2021 and later decreased 6.28% in 2022.
  • Biogen's Buildings stood at $1.7 billion in 2021, then fell by 6.28% to $1.6 billion in 2022, then rose by 0.53% to $1.6 billion in 2023, then grew by 22.63% to $2.0 billion in 2024, then increased by 8.99% to $2.1 billion in 2025.
  • The last three reported values for Buildings were $2.1 billion (Q4 2025), $2.0 billion (Q4 2024), and $1.6 billion (Q4 2023) per Business Quant data.